{"transactions":[{"id":2230842,"issuer":{"id":95904,"kind":"organization","name":"MIDWEST HOLDING INC.","symbol":"MDWT"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126117,"kind":"person","name":"CRESTLINE ASSURANCE HOLDINGS LLC","position":2,"cik":"0001810802","reported_name":"CRESTLINE ASSURANCE HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":3,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2022-06-16T16:07:17.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":2674,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2022, the Board of Directors (the \"Board\") of Midwest Holding Inc. (the \"Issuer\") granted to Mr. Bratton, a member of the Board, 2,674 restricted stock units (\"RSUs\"). The RSUs vest 100% into shares of Voting Common Stock of the Issuer on a 1-for-1 basis on the earlier of the first anniversary of its date of grant and the date of the Issuer's next annual meeting of its stockholders, subject to Mr. Bratton's continued service on the Issuer's Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Bratton serves on the Issuer's Board as a representative of Crestline Assurance Holdings LLC (\"Crestline Assurance\") and its affiliates.  Mr. Bratton holds the RSUs reported herein for the benefit of Crestline Assurance and as a result does not have any direct pecuniary interest in such RSUs.  Mr. Bratton may be deemed to have an indirect pecuniary interest in a portion of the RSUs through indirect membership interests in Crestline Assurance. The Manager of Crestline Assurance is Mr. Bratton and the Sole Member of Crestline Assurance is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of Crestline Management. Mr. Bratton is the sole director of Crestline.  Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities beneficially owned by Crestline Assurance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2), Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":447845,"source":{"system":"sec-edgar","filing":"0000899243-22-022799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/355379/000089924322022799/doc4.xml","form_type":"4"}},{"id":2513872,"issuer":{"id":95904,"kind":"organization","name":"MIDWEST HOLDING INC.","symbol":"MDWT"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126117,"kind":"person","name":"CRESTLINE ASSURANCE HOLDINGS LLC","position":2,"cik":"0001810802","reported_name":"CRESTLINE ASSURANCE HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":3,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2021-11-15T16:18:42.000Z","date":"2021-11-11","kind":"grant","acquired":true,"shares":727,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On November 11, 2021, the Board of Directors (the \"Board\") of Midwest Holding Inc. (the \"Issuer\") granted to Mr. Bratton, a member of the Board, 727 restricted stock units (\"RSUs\"). The RSUs vest 100% into shares of Voting Common Stock of the Issuer on a 1-for-1 basis on the earlier of the first anniversary of its date of grant and the date of the Issuer's next annual meeting of its stockholders, subject to Mr. Bratton's continued service on the Issuer's Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Bratton serves on the Issuer's Board as a representative of Crestline Assurance Holdings LLC (\"Crestline Assurance\") and its affiliates.  Mr. Bratton holds the RSUs reported herein for the benefit of Crestline Assurance and as a result does not have any direct pecuniary interest in such RSUs.  Mr. Bratton may be deemed to have an indirect pecuniary interest in a portion of the RSUs through indirect membership interests in Crestline Assurance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Manager of Crestline Assurance is Mr. Bratton and the Sole Member of Crestline Assurance is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of Crestline Management. Mr. Bratton is the sole director of Crestline.  Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities beneficially owned by Crestline Assurance. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":445171,"source":{"system":"sec-edgar","filing":"0000899243-21-044580","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/355379/000089924321044580/doc4.xml","form_type":"4"}},{"id":2855010,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":3,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":5,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-17T20:39:21.000Z","date":"2021-02-12","kind":"sale","acquired":false,"shares":2216798,"price":65,"value":144091870.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of common stock of Denali Therapeutics Inc. (the \"Issuer\") are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL.  In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":9984836,"source":{"system":"sec-edgar","filing":"0000899243-21-007016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924321007016/doc4.xml","form_type":"4"}},{"id":3057380,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":3,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":5,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-14T16:50:58.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":1443247,"price":31.65,"value":45678767.55,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of common stock of Denali Therapeutics Inc. (the \"Issuer\") are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL.  In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued from footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":12201634,"source":{"system":"sec-edgar","filing":"0000899243-20-022430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924320022430/doc4.xml","form_type":"4"}},{"id":3070607,"issuer":{"id":95904,"kind":"organization","name":"MIDWEST HOLDING INC.","symbol":"MDWT"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126117,"kind":"person","name":"CRESTLINE ASSURANCE HOLDINGS LLC","position":2,"cik":"0001810802","reported_name":"CRESTLINE ASSURANCE HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":3,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-08-04T21:15:57.000Z","date":"2020-07-31","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Non-Qualified Stock Options granted under the Midwest Holding Inc. 2019 Long-Term Incentive Plan to Douglas K. Bratton for his service on the Board of Directors (the \"Board\") of Midwest Holding Inc. (the \"Issuer\"). The Non-Qualified Stock Options vest as follows: (i) 25,000 Options shall vest on July 31, 2022; and (ii) 25,000 Options shall vest on July 31, 2024, in each case subject to Mr. Bratton's continued service on the Issuer's Board."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Non-Qualified Stock Options granted under the Midwest Holding Inc. 2019 Long-Term Incentive Plan to Douglas K. Bratton for his service on the Board of Directors (the \"Board\") of Midwest Holding Inc. (the \"Issuer\"). The Non-Qualified Stock Options vest as follows: (i) 25,000 Options shall vest on July 31, 2022; and (ii) 25,000 Options shall vest on July 31, 2024, in each case subject to Mr. Bratton's continued service on the Issuer's Board."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Mr. Bratton serves on the Issuer's Board as a representative of Crestline Assurance Holdings LLC (\"Crestline Assurance\") and its affiliates.  Mr. Bratton holds the Options reported herein for the benefit of Crestline Assurance and as a result does not have any direct pecuniary interest in such Options.  Mr. Bratton may be deemed to have an indirect pecuniary interest in a portion of the Options through indirect membership interests in Crestline Assurance. The Manager of Crestline Assurance is Mr. Bratton and the Sole Member of Crestline Assurance is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of Crestline Management. Mr. Bratton is the sole director of Crestline.  Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities beneficially owned by Crestline Assurance."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":50000,"derivative":{"exercise_price":0.05,"expiration_date":"2020-07-31","underlying":"Voting Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-021314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/355379/000089924320021314/doc4.xml","form_type":"4"}},{"id":3116700,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":3,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":5,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T16:10:10.000Z","date":"2020-06-05","kind":"sale","acquired":false,"shares":1922855,"price":25.75,"value":49513516.25,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of common stock of Denali Therapeutics Inc. (the \"Issuer\") are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL.  In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(Continued in footnote 1) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":13644881,"source":{"system":"sec-edgar","filing":"0000899243-20-015779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924320015779/doc4.xml","form_type":"4"}},{"id":3241380,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":3,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":4,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":5,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-28T16:25:06.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":3894764,"price":20.25,"value":78868971.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of common stock of Denali Therapeutics Inc. (the \"Issuer\") are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL.  In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"(continued from footnote 1) Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":15567736,"source":{"system":"sec-edgar","filing":"0000899243-20-006252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924320006252/doc4.xml","form_type":"4"}},{"id":4131906,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131905,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":128200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":128200},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131904,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":743599,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":743599},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131903,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":1875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1875000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131902,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":2500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2500000},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131901,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":false,"shares":14499999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14499999},"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131900,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"purchase","acquired":true,"shares":275000,"price":18,"value":4950000.0,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":19462499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131899,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":240000,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":1111799,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131898,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":128200,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":871799,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131897,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":743599,"ownership":{"direct":false,"nature":"By Neuro Line Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held directly by Neuro Line Partners, L.P. (\"Neuro Line\").  The general partner of Neuro Line is Bratton Capital Management, L.P. (\"Bratton Capital Management\").  The general partner of Bratton Capital Management is Bratton Capital, Inc. (\"Bratton Capital\").  Douglas K. Bratton is the sole director of Bratton Capital.  Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"(Continued from Footnote 6) In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line.  Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":743599,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131896,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":1875000,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"All shares of Series B-1 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":19187499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131895,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":2500000,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"All shares of Series A-2 Convertible Preferred Stock of the Issuer automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":17312499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4131894,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142564,"kind":"organization","name":"AKDL, L.P.","position":2,"cik":"0001716958","reported_name":"AKDL, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144412,"kind":"organization","name":"Neuro Line Partners LP","position":3,"cik":"0001723842","reported_name":"Neuro Line Partners LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":4,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":5,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":98891,"kind":"organization","name":"Bratton Capital Management, L.P.","position":6,"cik":"0001723787","reported_name":"Bratton Capital Management, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141272,"kind":"organization","name":"Bratton Capital Inc.","position":7,"cik":"0001723783","reported_name":"Bratton Capital Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":8,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-12-14T16:09:47.000Z","date":"2017-12-12","kind":"exercise","acquired":true,"shares":14499999,"ownership":{"direct":false,"nature":"By AKDL, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All shares of Series A-1 Convertible Preferred Stock of Denali Therapeutics Inc. (the \"Issuer\") automatically converted into shares of common stock of the Issuer at a one-for-one ratio immediately prior to the completion of the Issuer's initial public offering of common stock and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held directly by AKDL, L.P. (\"AKDL\").  The general partner of AKDL is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of AKDL is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) In addition, Crestline SI, Crestline and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner interests, including limited partner profit interests, and/or general partner interests in AKDL.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL.  Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein."}],"balance_after":14812499,"source":{"system":"sec-edgar","filing":"0000899243-17-028694","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716958/000089924317028694/doc4.xml","form_type":"4"}},{"id":4256364,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":85440,"kind":"person","name":"BRATTON DOUGLAS K","position":1,"cik":"0001281933","reported_name":"BRATTON DOUGLAS K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":126118,"kind":"person","name":"Crestline Investors, Inc.","position":2,"cik":"0001626596","reported_name":"Crestline Investors, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":142565,"kind":"organization","name":"Crestline SI (GP), L.P.","position":3,"cik":"0001626597","reported_name":"Crestline SI (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":97110,"kind":"organization","name":"Crestline Management, L.P.","position":4,"cik":"0001536054","reported_name":"Crestline Management, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":174395,"kind":"organization","name":"CL Alaska, L.P.","position":5,"cik":"0001626595","reported_name":"CL Alaska, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-17T17:48:16.000Z","date":"2017-07-13","kind":"sale","acquired":false,"shares":8000000,"price":27,"value":216000000.0,"ownership":{"direct":false,"nature":"By CL Alaska, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchase reported in Column 4 occurred in a block transaction at a price of $27.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These 9,166,130 shares of the Issuer are held directly by CL Alaska, L.P. (\"CLA\").  The general partner of CLA is Crestline SI (GP), L.P. (\"Crestline SI\") and the investment manager of CLA is Crestline Management, L.P. (\"Crestline Management\").  Crestline Investors, Inc. (\"Crestline\") is the general partner of both Crestline SI and Crestline Management.  Douglas K. Bratton is the sole director of Crestline.  CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer as well as a partial pecuniary interest in the shares held by CLA.  Mr. Bratton does not intend to sell additional shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from footnote 2) CLA may be deemed to directly beneficially own all of these shares of the Issuer.  Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer.  Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein."}],"balance_after":9166130,"source":{"system":"sec-edgar","filing":"0000899243-17-018338","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281933/000089924317018338/doc4.xml","form_type":"4"}}]}